Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.9 NOK | +1.70% | 0.00% | +2.58% |
04-24 | Vistin Pharma ASA Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-24 | Transcript : Vistin Pharma ASA, Q1 2024 Earnings Call, Apr 24, 2024 |
Sales 2021 | 279M 25.27M 2.02B | Sales 2022 | 305M 27.65M 2.21B | Capitalization | 701M 63.55M 5.08B |
---|---|---|---|---|---|
Net income 2021 | 24M 2.18M 174M | Net income 2022 | -4M -363K -29.02M | EV / Sales 2021 | 2.96 x |
Net cash position 2021 | 34.36M 3.12M 249M | Net Debt 2022 | 47.73M 4.33M 346M | EV / Sales 2022 | 2.45 x |
P/E ratio 2021 |
34.6
x | P/E ratio 2022 |
-144
x | Employees | 78 |
Yield 2021 |
3.87% | Yield 2022 |
4.75% | Free-Float | 45.24% |
Latest transcript on Vistin Pharma ASA
1 day | +1.70% | ||
Current month | +7.17% | ||
1 month | +4.37% | ||
3 months | +3.91% | ||
6 months | +4.82% | ||
Current year | +2.58% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 29/02/20 | |
Director of Finance/CFO | - | 01/03/20 | |
Eivind Egeli
CTO | Chief Tech/Sci/R&D Officer | - | 31/05/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 76 | 31/05/20 | |
Director/Board Member | 62 | 05/03/15 | |
Director/Board Member | 60 | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 23.9 | +1.70% | 1,465 |
25/04/24 | 23.5 | 0.00% | 9,730 |
24/04/24 | 23.5 | -3.29% | 39,831 |
23/04/24 | 24.3 | +0.41% | 16,505 |
22/04/24 | 24.2 | +1.26% | 6,225 |
Real-time Oslo Bors, April 26, 2024 at 03:45 pm
More quotes1st Jan change | Capi. | |
---|---|---|
+2.58% | 95.97M | |
+19.62% | 43.34B | |
+20.44% | 21.96B | |
+10.86% | 14.09B | |
+13.07% | 13.64B | |
+37.46% | 11.43B | |
-8.59% | 6.86B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+8.46% | 5.22B |
- Stock Market
- Equities
- VISTN Stock